Click for best price
Lung Cancer Diagnostics Market Size, Share 2024
| Market size in 2023 |
US$ 1776.5 million
|
Forecast Market size by 2030 |
US$ 2674.5 million
|
| Growth Rate |
CAGR of 6.0% |
Number of Pages |
117 Pages |
The global Lung Cancer Diagnostics market was valued at US$ 1776.5 million in 2023 and is projected to reach US$ 2674.5 million by 2030, at a CAGR of 6.0% during the forecast period.
The USA market for Global Lung Cancer Diagnostics market is estimated to increase from USD million in 2023 to reach USD million by 2030, at a CAGR during the forecast period of 2023 through 2030.
The China market for Global Lung Cancer Diagnostics market is estimated to increase from USD million in 2023 to reach USD million by 2030, at a CAGR during the forecast period of 2023 through 2030.
The Europe market for Global Lung Cancer Diagnostics market is estimated to increase from USD million in 2023 to reach USD million by 2030, at a CAGR during the forecast period of 2023 through 2030.
This research report provides a comprehensive analysis of the Lung Cancer Diagnostics market, focusing on the current trends, market dynamics, and future prospects. The report explores the global Lung Cancer Diagnostics market, including major regions such as North America, Europe, Asia-Pacific, and emerging markets. It also examines key factors driving the growth of Lung Cancer Diagnostics, challenges faced by the industry, and potential opportunities for market players.
The global Lung Cancer Diagnostics market has witnessed rapid growth in recent years, driven by increasing environmental concerns, government incentives, and advancements in technology. The Lung Cancer Diagnostics market presents opportunities for various stakeholders, including Industrial, Healthcare. Collaboration between the private sector and governments can accelerate the development of supportive policies, research and development efforts, and investment in Lung Cancer Diagnostics market. Additionally, the growing consumer demand present avenues for market expansion.
The global pharmaceutical market is 1475 billion USD in 2022, growing at a CAGR of 5% during the next six years. The pharmaceutical market includes chemical drugs and biological drugs. For biologics is expected to 381 billion USD in 2022. In comparison, the chemical drug market is estimated to increase from 1005 billion in 2018 to 1094 billion U.S. dollars in 2022. The pharmaceutical market factors such as increasing demand for healthcare, technological advancements, and the rising prevalence of chronic diseases, increase in funding from private & government organizations for development of pharmaceutical manufacturing segments and rise in R&D activities for drugs. However, the industry also faces challenges such as stringent regulations, high costs of research and development, and patent expirations. Companies need to continuously innovate and adapt to these challenges to stay competitive in the market and ensure their products reach patients in need. Additionally, the COVID-19 pandemic has highlighted the importance of vaccine development and supply chain management, further emphasizing the need for pharmaceutical companies to be agile and responsive to emerging public health needs.
Key Features:
The research report on the Lung Cancer Diagnostics market includes several key features to provide comprehensive insights and facilitate decision-making for stakeholders.
Executive Summary: The report provides overview of the key findings, market trends, and major insights of the Lung Cancer Diagnostics market.
Market Overview: The report provides a comprehensive overview of the Lung Cancer Diagnostics market, including its definition, historical development, and current market size. It covers market segmentation by Type (e.g., Immunoassays, Flow Cytometry), region, and application, highlighting the key drivers, challenges, and opportunities within each segment.
Market Dynamics: The report analyses the market dynamics driving the growth and development of the Lung Cancer Diagnostics market. The report includes an assessment of government policies and regulations, technological advancements, consumer trends and preferences, infrastructure development, and industry collaborations. This analysis helps stakeholders understand the factors influencing the Lung Cancer Diagnostics market's trajectory.
Competitive Landscape: The report provides an in-depth analysis of the competitive landscape within the Lung Cancer Diagnostics market. It includes profiles of major market players, their market share, strategies, product portfolios, and recent developments.
Market Segmentation and Forecast: The report segment the Lung Cancer Diagnostics market based on various parameters, such as by Type, region, and by Application. It provides market size and growth forecasts for each segment, supported by quantitative data and analysis. This helps stakeholders identify growth opportunities and make informed investment decisions.
Technological Trends: The report should highlight the key technological trends shaping the Lung Cancer Diagnostics market, such as advancements in Type One technology and emerging substitutes. It analyses the impact of these trends on market growth, adoption rates, and consumer preferences.
Market Challenges and Opportunities: The report identify and analyses the major challenges faced by the Lung Cancer Diagnostics market, such as technical bottleneck, cost limitations, and high entry barrier. It also highlights the opportunities for market growth, such as government incentives, emerging markets, and collaborations between stakeholders.
Regulatory and Policy Analysis: The report should assess the regulatory and policy landscape for Lung Cancer Diagnostics, including government incentives, emission standards, and infrastructure development plans. It should analyse the impact of these policies on market growth and provide insights into future regulatory developments.
Recommendations and Conclusion: The report conclude with actionable recommendations for stakeholders, such as Application One Consumer, policymakers, investors, and infrastructure providers. These recommendations should be based on the research findings and address key challenges and opportunities within the Lung Cancer Diagnostics market.
Supporting Data and Appendices: The report include supporting data, charts, and graphs to substantiate the analysis and findings. It also includes appendices with additional detailed information, such as data sources, survey questionnaires, and detailed market forecasts.
Market Segmentation
Lung Cancer Diagnostics market is split by Type and by Application. For the period 2019-2030, the growth among segments provides accurate calculations and forecasts for consumption value by Type, and by Application in terms of value.
Market segment by Type
- Immunoassays
- Flow Cytometry
- Rapid Tests
- Molecular Assays
- Tissue Arrays
- Circulating Tumor Cells
- Pharmacodiagnostics
- Biomarkers
- Other
Market segment by Application
- Industrial
- Healthcare
- Other
Global Lung Cancer Diagnostics Market Segment Percentages, By Region and Country, 2023 (%)
- North America
- US
- Canada
- Mexico
- Europe
- Germany
- France
- U.K.
- Italy
- Russia
- Nordic Countries
- Benelux
- Rest of Europe
- Asia
- China
- Japan
- South Korea
- Southeast Asia
- India
- Rest of Asia
- South America
- Brazil
- Argentina
- Rest of South America
- Middle East & Africa
- Turkey
- Israel
- Saudi Arabia
- UAE
- Rest of Middle East & Africa
Major players covered
- Roche Diagnostics
- BioMrieux
- Qiagen
- Advpharma
- AIT Austrian Institute of Technology
- Courtagen Life Sciences
- DiagnoCure
- BioMark Diagnostics
- Mayo Clinic
- HalioDx SAS
Outline of Major Chapters:
Chapter 1: Introduces the definition of Lung Cancer Diagnostics, market overview.
Chapter 2: Global Lung Cancer Diagnostics market size in revenue.
Chapter 3: Detailed analysis of Lung Cancer Diagnostics company competitive landscape, revenue and market share, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6: Sales of Lung Cancer Diagnostics in regional level and country level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space of each country in the world.
Chapter 7: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 8: The main points and conclusions of the report.
| Report Attributes |
Report Details |
| Report Title |
Lung Cancer Diagnostics Market, Global Outlook and Forecast 2024-2030 |
| Market size in 2023 |
US$ 1776.5 million
|
| Forecast Market size by 2030 |
US$ 2674.5 million
|
| Growth Rate |
CAGR of 6.0% |
| Historical Year |
2018 to 2022 (Data from 2010 can be provided as per availability) |
| Base Year |
2023 |
| Forecast Year |
2031 |
| Number of Pages |
117 Pages |
| Customization Available |
Yes, the report can be customized as per your need. |
TABLE OF CONTENTS
1 Introduction to Research & Analysis Reports
1.1 Lung Cancer Diagnostics Market Definition
1.2 Market Segments
1.2.1 Market by Type
1.2.2 Market by Application
1.3 Global Lung Cancer Diagnostics Market Overview
1.4 Features & Benefits of This Report
1.5 Methodology & Sources of Information
1.5.1 Research Methodology
1.5.2 Research Process
1.5.3 Base Year
1.5.4 Report Assumptions & Caveats
2 Global Lung Cancer Diagnostics Overall Market Size
2.1 Global Lung Cancer Diagnostics Market Size: 2023 VS 2030
2.2 Global Lung Cancer Diagnostics Market Size, Prospects & Forecasts: 2019-2030
2.3 Key Market Trends, Opportunity, Drivers and Restraints
2.3.1 Market Opportunities & Trends
2.3.2 Market Drivers
2.3.3 Market Restraints
3 Company Landscape
3.1 Top Lung Cancer Diagnostics Players in Global Market
3.2 Top Global Lung Cancer Diagnostics Companies Ranked by Revenue
3.3 Global Lung Cancer Diagnostics Revenue by Companies
3.4 Top 3 and Top 5 Lung Cancer Diagnostics Companies in Global Market, by Revenue in 2023
3.5 Global Companies Lung Cancer Diagnostics Product Type
3.6 Tier 1, Tier 2 and Tier 3 Lung Cancer Diagnostics Players in Global Market
3.6.1 List of Global Tier 1 Lung Cancer Diagnostics Companies
3.6.2 List of Global Tier 2 and Tier 3 Lung Cancer Diagnostics Companies
4 Market Sights by Product
4.1 Overview
4.1.1 By Type - Global Lung Cancer Diagnostics Market Size Markets, 2023 & 2030
4.1.2 Immunoassays
4.1.3 Flow Cytometry
4.1.4 Rapid Tests
4.1.5 Molecular Assays
4.1.6 Tissue Arrays
4.1.7 Circulating Tumor Cells
4.1.8 Pharmacodiagnostics
4.1.9 Biomarkers
4.1.10 Other
4.2 By Type - Global Lung Cancer Diagnostics Revenue & Forecasts
4.2.1 By Type - Global Lung Cancer Diagnostics Revenue, 2019-2024
4.2.2 By Type - Global Lung Cancer Diagnostics Revenue, 2025-2030
4.2.3 By Type - Global Lung Cancer Diagnostics Revenue Market Share, 2019-2030
5 Sights by Application
5.1 Overview
5.1.1 By Application - Global Lung Cancer Diagnostics Market Size, 2023 & 2030
5.1.2 Industrial
5.1.3 Healthcare
5.1.4 Other
5.2 By Application - Global Lung Cancer Diagnostics Revenue & Forecasts
5.2.1 By Application - Global Lung Cancer Diagnostics Revenue, 2019-2024
5.2.2 By Application - Global Lung Cancer Diagnostics Revenue, 2025-2030
5.2.3 By Application - Global Lung Cancer Diagnostics Revenue Market Share, 2019-2030
6 Sights by Region
6.1 By Region - Global Lung Cancer Diagnostics Market Size, 2023 & 2030
6.2 By Region - Global Lung Cancer Diagnostics Revenue & Forecasts
6.2.1 By Region - Global Lung Cancer Diagnostics Revenue, 2019-2024
6.2.2 By Region - Global Lung Cancer Diagnostics Revenue, 2025-2030
6.2.3 By Region - Global Lung Cancer Diagnostics Revenue Market Share, 2019-2030
6.3 North America
6.3.1 By Country - North America Lung Cancer Diagnostics Revenue, 2019-2030
6.3.2 US Lung Cancer Diagnostics Market Size, 2019-2030
6.3.3 Canada Lung Cancer Diagnostics Market Size, 2019-2030
6.3.4 Mexico Lung Cancer Diagnostics Market Size, 2019-2030
6.4 Europe
6.4.1 By Country - Europe Lung Cancer Diagnostics Revenue, 2019-2030
6.4.2 Germany Lung Cancer Diagnostics Market Size, 2019-2030
6.4.3 France Lung Cancer Diagnostics Market Size, 2019-2030
6.4.4 U.K. Lung Cancer Diagnostics Market Size, 2019-2030
6.4.5 Italy Lung Cancer Diagnostics Market Size, 2019-2030
6.4.6 Russia Lung Cancer Diagnostics Market Size, 2019-2030
6.4.7 Nordic Countries Lung Cancer Diagnostics Market Size, 2019-2030
6.4.8 Benelux Lung Cancer Diagnostics Market Size, 2019-2030
6.5 Asia
6.5.1 By Region - Asia Lung Cancer Diagnostics Revenue, 2019-2030
6.5.2 China Lung Cancer Diagnostics Market Size, 2019-2030
6.5.3 Japan Lung Cancer Diagnostics Market Size, 2019-2030
6.5.4 South Korea Lung Cancer Diagnostics Market Size, 2019-2030
6.5.5 Southeast Asia Lung Cancer Diagnostics Market Size, 2019-2030
6.5.6 India Lung Cancer Diagnostics Market Size, 2019-2030
6.6 South America
6.6.1 By Country - South America Lung Cancer Diagnostics Revenue, 2019-2030
6.6.2 Brazil Lung Cancer Diagnostics Market Size, 2019-2030
6.6.3 Argentina Lung Cancer Diagnostics Market Size, 2019-2030
6.7 Middle East & Africa
6.7.1 By Country - Middle East & Africa Lung Cancer Diagnostics Revenue, 2019-2030
6.7.2 Turkey Lung Cancer Diagnostics Market Size, 2019-2030
6.7.3 Israel Lung Cancer Diagnostics Market Size, 2019-2030
6.7.4 Saudi Arabia Lung Cancer Diagnostics Market Size, 2019-2030
6.7.5 UAE Lung Cancer Diagnostics Market Size, 2019-2030
7 Lung Cancer Diagnostics Companies Profiles
7.1 Roche Diagnostics
7.1.1 Roche Diagnostics Company Summary
7.1.2 Roche Diagnostics Business Overview
7.1.3 Roche Diagnostics Lung Cancer Diagnostics Major Product Offerings
7.1.4 Roche Diagnostics Lung Cancer Diagnostics Revenue in Global Market (2019-2024)
7.1.5 Roche Diagnostics Key News & Latest Developments
7.2 BioM?rieux
7.2.1 BioM?rieux Company Summary
7.2.2 BioM?rieux Business Overview
7.2.3 BioM?rieux Lung Cancer Diagnostics Major Product Offerings
7.2.4 BioM?rieux Lung Cancer Diagnostics Revenue in Global Market (2019-2024)
7.2.5 BioM?rieux Key News & Latest Developments
7.3 Qiagen
7.3.1 Qiagen Company Summary
7.3.2 Qiagen Business Overview
7.3.3 Qiagen Lung Cancer Diagnostics Major Product Offerings
7.3.4 Qiagen Lung Cancer Diagnostics Revenue in Global Market (2019-2024)
7.3.5 Qiagen Key News & Latest Developments
7.4 Advpharma
7.4.1 Advpharma Company Summary
7.4.2 Advpharma Business Overview
7.4.3 Advpharma Lung Cancer Diagnostics Major Product Offerings
7.4.4 Advpharma Lung Cancer Diagnostics Revenue in Global Market (2019-2024)
7.4.5 Advpharma Key News & Latest Developments
7.5 AIT Austrian Institute of Technology
7.5.1 AIT Austrian Institute of Technology Company Summary
7.5.2 AIT Austrian Institute of Technology Business Overview
7.5.3 AIT Austrian Institute of Technology Lung Cancer Diagnostics Major Product Offerings
7.5.4 AIT Austrian Institute of Technology Lung Cancer Diagnostics Revenue in Global Market (2019-2024)
7.5.5 AIT Austrian Institute of Technology Key News & Latest Developments
7.6 Courtagen Life Sciences
7.6.1 Courtagen Life Sciences Company Summary
7.6.2 Courtagen Life Sciences Business Overview
7.6.3 Courtagen Life Sciences Lung Cancer Diagnostics Major Product Offerings
7.6.4 Courtagen Life Sciences Lung Cancer Diagnostics Revenue in Global Market (2019-2024)
7.6.5 Courtagen Life Sciences Key News & Latest Developments
7.7 DiagnoCure
7.7.1 DiagnoCure Company Summary
7.7.2 DiagnoCure Business Overview
7.7.3 DiagnoCure Lung Cancer Diagnostics Major Product Offerings
7.7.4 DiagnoCure Lung Cancer Diagnostics Revenue in Global Market (2019-2024)
7.7.5 DiagnoCure Key News & Latest Developments
7.8 BioMark Diagnostics
7.8.1 BioMark Diagnostics Company Summary
7.8.2 BioMark Diagnostics Business Overview
7.8.3 BioMark Diagnostics Lung Cancer Diagnostics Major Product Offerings
7.8.4 BioMark Diagnostics Lung Cancer Diagnostics Revenue in Global Market (2019-2024)
7.8.5 BioMark Diagnostics Key News & Latest Developments
7.9 Mayo Clinic
7.9.1 Mayo Clinic Company Summary
7.9.2 Mayo Clinic Business Overview
7.9.3 Mayo Clinic Lung Cancer Diagnostics Major Product Offerings
7.9.4 Mayo Clinic Lung Cancer Diagnostics Revenue in Global Market (2019-2024)
7.9.5 Mayo Clinic Key News & Latest Developments
7.10 HalioDx SAS
7.10.1 HalioDx SAS Company Summary
7.10.2 HalioDx SAS Business Overview
7.10.3 HalioDx SAS Lung Cancer Diagnostics Major Product Offerings
7.10.4 HalioDx SAS Lung Cancer Diagnostics Revenue in Global Market (2019-2024)
7.10.5 HalioDx SAS Key News & Latest Developments
8 Conclusion
9 Appendix
9.1 Note
9.2 Examples of Clients
9.3 Disclaimer
LIST OF TABLES & FIGURES
List of Tables
Table 1. Lung Cancer Diagnostics Market Opportunities & Trends in Global Market
Table 2. Lung Cancer Diagnostics Market Drivers in Global Market
Table 3. Lung Cancer Diagnostics Market Restraints in Global Market
Table 4. Key Players of Lung Cancer Diagnostics in Global Market
Table 5. Top Lung Cancer Diagnostics Players in Global Market, Ranking by Revenue (2023)
Table 6. Global Lung Cancer Diagnostics Revenue by Companies, (US$, Mn), 2019-2024
Table 7. Global Lung Cancer Diagnostics Revenue Share by Companies, 2019-2024
Table 8. Global Companies Lung Cancer Diagnostics Product Type
Table 9. List of Global Tier 1 Lung Cancer Diagnostics Companies, Revenue (US$, Mn) in 2023 and Market Share
Table 10. List of Global Tier 2 and Tier 3 Lung Cancer Diagnostics Companies, Revenue (US$, Mn) in 2023 and Market Share
Table 11. By Type ? Global Lung Cancer Diagnostics Revenue, (US$, Mn), 2023 & 2030
Table 12. By Type - Lung Cancer Diagnostics Revenue in Global (US$, Mn), 2019-2024
Table 13. By Type - Lung Cancer Diagnostics Revenue in Global (US$, Mn), 2025-2030
Table 14. By Application ? Global Lung Cancer Diagnostics Revenue, (US$, Mn), 2023 & 2030
Table 15. By Application - Lung Cancer Diagnostics Revenue in Global (US$, Mn), 2019-2024
Table 16. By Application - Lung Cancer Diagnostics Revenue in Global (US$, Mn), 2025-2030
Table 17. By Region ? Global Lung Cancer Diagnostics Revenue, (US$, Mn), 2023 & 2030
Table 18. By Region - Global Lung Cancer Diagnostics Revenue (US$, Mn), 2019-2024
Table 19. By Region - Global Lung Cancer Diagnostics Revenue (US$, Mn), 2025-2030
Table 20. By Country - North America Lung Cancer Diagnostics Revenue, (US$, Mn), 2019-2024
Table 21. By Country - North America Lung Cancer Diagnostics Revenue, (US$, Mn), 2025-2030
Table 22. By Country - Europe Lung Cancer Diagnostics Revenue, (US$, Mn), 2019-2024
Table 23. By Country - Europe Lung Cancer Diagnostics Revenue, (US$, Mn), 2025-2030
Table 24. By Region - Asia Lung Cancer Diagnostics Revenue, (US$, Mn), 2019-2024
Table 25. By Region - Asia Lung Cancer Diagnostics Revenue, (US$, Mn), 2025-2030
Table 26. By Country - South America Lung Cancer Diagnostics Revenue, (US$, Mn), 2019-2024
Table 27. By Country - South America Lung Cancer Diagnostics Revenue, (US$, Mn), 2025-2030
Table 28. By Country - Middle East & Africa Lung Cancer Diagnostics Revenue, (US$, Mn), 2019-2024
Table 29. By Country - Middle East & Africa Lung Cancer Diagnostics Revenue, (US$, Mn), 2025-2030
Table 30. Roche Diagnostics Company Summary
Table 31. Roche Diagnostics Lung Cancer Diagnostics Product Offerings
Table 32. Roche Diagnostics Lung Cancer Diagnostics Revenue (US$, Mn) & (2019-2024)
Table 33. Roche Diagnostics Key News & Latest Developments
Table 34. BioM?rieux Company Summary
Table 35. BioM?rieux Lung Cancer Diagnostics Product Offerings
Table 36. BioM?rieux Lung Cancer Diagnostics Revenue (US$, Mn) & (2019-2024)
Table 37. BioM?rieux Key News & Latest Developments
Table 38. Qiagen Company Summary
Table 39. Qiagen Lung Cancer Diagnostics Product Offerings
Table 40. Qiagen Lung Cancer Diagnostics Revenue (US$, Mn) & (2019-2024)
Table 41. Qiagen Key News & Latest Developments
Table 42. Advpharma Company Summary
Table 43. Advpharma Lung Cancer Diagnostics Product Offerings
Table 44. Advpharma Lung Cancer Diagnostics Revenue (US$, Mn) & (2019-2024)
Table 45. Advpharma Key News & Latest Developments
Table 46. AIT Austrian Institute of Technology Company Summary
Table 47. AIT Austrian Institute of Technology Lung Cancer Diagnostics Product Offerings
Table 48. AIT Austrian Institute of Technology Lung Cancer Diagnostics Revenue (US$, Mn) & (2019-2024)
Table 49. AIT Austrian Institute of Technology Key News & Latest Developments
Table 50. Courtagen Life Sciences Company Summary
Table 51. Courtagen Life Sciences Lung Cancer Diagnostics Product Offerings
Table 52. Courtagen Life Sciences Lung Cancer Diagnostics Revenue (US$, Mn) & (2019-2024)
Table 53. Courtagen Life Sciences Key News & Latest Developments
Table 54. DiagnoCure Company Summary
Table 55. DiagnoCure Lung Cancer Diagnostics Product Offerings
Table 56. DiagnoCure Lung Cancer Diagnostics Revenue (US$, Mn) & (2019-2024)
Table 57. DiagnoCure Key News & Latest Developments
Table 58. BioMark Diagnostics Company Summary
Table 59. BioMark Diagnostics Lung Cancer Diagnostics Product Offerings
Table 60. BioMark Diagnostics Lung Cancer Diagnostics Revenue (US$, Mn) & (2019-2024)
Table 61. BioMark Diagnostics Key News & Latest Developments
Table 62. Mayo Clinic Company Summary
Table 63. Mayo Clinic Lung Cancer Diagnostics Product Offerings
Table 64. Mayo Clinic Lung Cancer Diagnostics Revenue (US$, Mn) & (2019-2024)
Table 65. Mayo Clinic Key News & Latest Developments
Table 66. HalioDx SAS Company Summary
Table 67. HalioDx SAS Lung Cancer Diagnostics Product Offerings
Table 68. HalioDx SAS Lung Cancer Diagnostics Revenue (US$, Mn) & (2019-2024)
Table 69. HalioDx SAS Key News & Latest Developments
List of Figures
Figure 1. Lung Cancer Diagnostics Segment by Type in 2023
Figure 2. Lung Cancer Diagnostics Segment by Application in 2023
Figure 3. Global Lung Cancer Diagnostics Market Overview: 2023
Figure 4. Key Caveats
Figure 5. Global Lung Cancer Diagnostics Market Size: 2023 VS 2030 (US$, Mn)
Figure 6. Global Lung Cancer Diagnostics Revenue, 2019-2030 (US$, Mn)
Figure 7. The Top 3 and 5 Players Market Share by Lung Cancer Diagnostics Revenue in 2023
Figure 8. By Type - Global Lung Cancer Diagnostics Revenue Market Share, 2019-2030
Figure 9. By Application - Global Lung Cancer Diagnostics Revenue Market Share, 2019-2030
Figure 10. By Type - Global Lung Cancer Diagnostics Revenue, (US$, Mn), 2023 & 2030
Figure 11. By Type - Global Lung Cancer Diagnostics Revenue Market Share, 2019-2030
Figure 12. By Application - Global Lung Cancer Diagnostics Revenue, (US$, Mn), 2023 & 2030
Figure 13. By Application - Global Lung Cancer Diagnostics Revenue Market Share, 2019-2030
Figure 14. By Region - Global Lung Cancer Diagnostics Revenue Market Share, 2019-2030
Figure 15. By Country - North America Lung Cancer Diagnostics Revenue Market Share, 2019-2030
Figure 16. US Lung Cancer Diagnostics Revenue, (US$, Mn), 2019-2030
Figure 17. Canada Lung Cancer Diagnostics Revenue, (US$, Mn), 2019-2030
Figure 18. Mexico Lung Cancer Diagnostics Revenue, (US$, Mn), 2019-2030
Figure 19. By Country - Europe Lung Cancer Diagnostics Revenue Market Share, 2019-2030
Figure 20. Germany Lung Cancer Diagnostics Revenue, (US$, Mn), 2019-2030
Figure 21. France Lung Cancer Diagnostics Revenue, (US$, Mn), 2019-2030
Figure 22. U.K. Lung Cancer Diagnostics Revenue, (US$, Mn), 2019-2030
Figure 23. Italy Lung Cancer Diagnostics Revenue, (US$, Mn), 2019-2030
Figure 24. Russia Lung Cancer Diagnostics Revenue, (US$, Mn), 2019-2030
Figure 25. Nordic Countries Lung Cancer Diagnostics Revenue, (US$, Mn), 2019-2030
Figure 26. Benelux Lung Cancer Diagnostics Revenue, (US$, Mn), 2019-2030
Figure 27. By Region - Asia Lung Cancer Diagnostics Revenue Market Share, 2019-2030
Figure 28. China Lung Cancer Diagnostics Revenue, (US$, Mn), 2019-2030
Figure 29. Japan Lung Cancer Diagnostics Revenue, (US$, Mn), 2019-2030
Figure 30. South Korea Lung Cancer Diagnostics Revenue, (US$, Mn), 2019-2030
Figure 31. Southeast Asia Lung Cancer Diagnostics Revenue, (US$, Mn), 2019-2030
Figure 32. India Lung Cancer Diagnostics Revenue, (US$, Mn), 2019-2030
Figure 33. By Country - South America Lung Cancer Diagnostics Revenue Market Share, 2019-2030
Figure 34. Brazil Lung Cancer Diagnostics Revenue, (US$, Mn), 2019-2030
Figure 35. Argentina Lung Cancer Diagnostics Revenue, (US$, Mn), 2019-2030
Figure 36. By Country - Middle East & Africa Lung Cancer Diagnostics Revenue Market Share, 2019-2030
Figure 37. Turkey Lung Cancer Diagnostics Revenue, (US$, Mn), 2019-2030
Figure 38. Israel Lung Cancer Diagnostics Revenue, (US$, Mn), 2019-2030
Figure 39. Saudi Arabia Lung Cancer Diagnostics Revenue, (US$, Mn), 2019-2030
Figure 40. UAE Lung Cancer Diagnostics Revenue, (US$, Mn), 2019-2030
Figure 41. Roche Diagnostics Lung Cancer Diagnostics Revenue Year Over Year Growth (US$, Mn) & (2019-2024)
Figure 42. BioM?rieux Lung Cancer Diagnostics Revenue Year Over Year Growth (US$, Mn) & (2019-2024)
Figure 43. Qiagen Lung Cancer Diagnostics Revenue Year Over Year Growth (US$, Mn) & (2019-2024)
Figure 44. Advpharma Lung Cancer Diagnostics Revenue Year Over Year Growth (US$, Mn) & (2019-2024)
Figure 45. AIT Austrian Institute of Technology Lung Cancer Diagnostics Revenue Year Over Year Growth (US$, Mn) & (2019-2024)
Figure 46. Courtagen Life Sciences Lung Cancer Diagnostics Revenue Year Over Year Growth (US$, Mn) & (2019-2024)
Figure 47. DiagnoCure Lung Cancer Diagnostics Revenue Year Over Year Growth (US$, Mn) & (2019-2024)
Figure 48. BioMark Diagnostics Lung Cancer Diagnostics Revenue Year Over Year Growth (US$, Mn) & (2019-2024)
Figure 49. Mayo Clinic Lung Cancer Diagnostics Revenue Year Over Year Growth (US$, Mn) & (2019-2024)
Figure 50. HalioDx SAS Lung Cancer Diagnostics Revenue Year Over Year Growth (US$, Mn) & (2019-2024)
